Borchgrevink C F, Bjerkelund C, Abrahamsen A M, Bay G, Borgen P, Grande B, Helle I, Kjörstad H, Petersen A M, Rörvik T, Thorsen R, Odegaard A
Br Med J. 1968 Sep 7;3(5618):571-4. doi: 10.1136/bmj.3.5618.571.
A multicentre trial from five medical departments in Oslo has been carried out to determine the value in women patients of one year's long-term anticoagulant therapy. Follow-up long-term laboratory control and anticoagulant dosage were performed at one centre (the Rikshospitalet). One hundred and fifty-nine patients were assigned randomly into two similar well-matched groups (control and treatment). Dosage was controlled by Thrombotest, aiming at 10-20% levels, and 50% of the tests were less than 14%. Compared with the control group, the treatment group showed a significant reduction in mortality and in reinfarction rate. No serious bleeding complications occurred. It is concluded that women benefit as much as men from long-term anticoagulant therapy.
奥斯陆五个医学科室开展了一项多中心试验，以确定为期一年的长期抗凝治疗对女性患者的价值。长期实验室监测及抗凝剂剂量调整在一个中心（国家医院）进行。159名患者被随机分为两个匹配良好的相似组（对照组和治疗组）。通过凝血试验控制剂量，目标水平为10%-20%，且50%的检测结果低于14%。与对照组相比，治疗组的死亡率和再梗死率显著降低。未发生严重出血并发症。研究得出结论，长期抗凝治疗对女性和男性的益处相同。
